Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Palobiofarma partners lung cancer candidate with Novartis

Executive Summary

Novartis AG licensed exclusive worldwide rights to develop, manufacture, and commercialize Palobiofarma SL's Phase I PBF509 for non-small cell lung cancer. The Big Pharma also received rights to patents covering the role of adenosine in immunotherapy.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register